Rosatom creates an international platform for the development of radiopharmaceuticals based on terbium-161

The project aims to improve the effectiveness of cancer treatment with minimal side effects

Rosatom has initiated the creation of an international platform for the development of radiopharmaceuticals based on terbium-161, which can improve the effectiveness of cancer treatment and reduce the side effects of therapy. This was announced at the "World Nuclear Week" forum.

We propose to form a multinational expert group that will combine technologies for the production of the radionuclide, methods for its purification, the development of promising radiopharmaceuticals, and the exchange of clinical results
Sergey Surov, Director of Radioisotope Products and Nuclear Medicine at Rosatom Science JSC

The project is designed for three years with the possibility of extension and includes regular publication of results in peer-reviewed scientific journals.

Technologies used for the production and use of lutetium-177 can be adapted for terbium-161. The additional effect of terbium-161 electrons allows to increase the effectiveness of therapy with minimal damage to healthy tissues.

The scientific division of Rosatom manages 12 research centers, nine reactors, and more than 700 experimental facilities, and produces over ten radiopharmaceuticals. A large radiopharmaceutical plant is under construction in Obninsk, scheduled to launch next year.

Read more on the topic:

Sources
TASS

Now on home